Shattuck Labs, Inc.
STTKHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeShattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The $551.0M market capitalization puts STTK squarely in small-cap range for its industry. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Market Cap
$551.0M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-10.62
EPS (TTM)
$-0.47
EPS (Fwd)
$-0.52
ROE
-39.2%
ROA
-24.4%
Cash
$208.3M
Total Debt
$2.7M
Free CF
-$21.2M
52W Change
166.5%
Annual Financials
Cash vs Debt
Where STTK stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, STTK finished 8.29% below its 150-day moving average ($6.51) and 0.84% above its 200-day moving average ($5.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STTK overbought or oversold?
At the October 12, 2026 close, STTK's RSI(14) was 47.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $208.3M in cash and $2.7M in debt, STTK maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$21.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -39.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $652K (2022) to $1.0M (2025), reflecting a 53% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Shattuck Labs, Inc. and its sector.